As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

First two GMP doses of rese-cel manufactured on the Cell Shuttle(TM) met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET(TM) ...

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), ...

The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.

Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...

Kincell Bio, a leading contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell ...

For Astellas’ chief manufacturing officer Rao Mantri, Ph.D.—who entered the position a little over a year ago—production is ...

In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...

Personalized cell therapies have emerged as powerful treatments for cancers and other diseases but producing them remains a complex engineering challenge. Unlike conventional drugs, each cell therapy ...

Raguneprocel, a stem cell-based dopamine neuron replacement therapy for treating motor symptoms in Parkinson’s disease (PD), ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s ("Cabaletta Bio" or "Cabaletta") (Nasdaq: CABA) investigational CAR T cell ...